viewCytoDyn Inc.

Full interview: CytoDyn CEO says FDA OK to begin Phase 2 to treat colon cancer just 'tip of the iceberg'

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive the FDA has given the greenlight to its Phase 2 protocol for a combination therapy of leronlimab and Regorafenib to treat patients with metastatic colorectal cancer, and this news is just the 'tip of the iceberg' for the biotech.

Pourhassan says the Vancouver, Washington-based biotechnology company said the FDA took around thirty days to review and approve the company to begin its proposed 60-patient clinical investigation.

Quick facts: CytoDyn Inc.

Price: 4.974 USD

Market: OTCQB
Market Cap: $2.58 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...



CytoDyn addresses negative claims made by healthcare publication STAT on its...

CytoDyn (OTCQB:CYDY) CEO Nader Pourhassan spoke to Proactive, addressing negative claims made by healthcare publication STAT on its coronavirus study. Pourhassan says the company has released what he says are positive results from its coronavirus treatment clinical study, and explains why he...

2 days, 20 hours ago

2 min read